Insider: Aftab Blake Chief Scientific Officer - Adicet Bio, Inc.
| Company Holdings |
| Direct | Indirect Ownership | Total | |
| Shares | 28,209 | 0 | 28,209 |
| Value | $23,661.71 | $0.00 | $23,661.71 |
Trans. Date |
Trans. Type |
Shares |
Ownership Type |
Issue Type |
Price |
Trans. Value |
Total Shares Owned |
|---|---|---|---|---|---|---|---|
| 11/10/2022 | DDS | 6,967 | Direct | COM | $21.00 | $146,307.00 | 28,209 |
| 10/19/2022 | DDS | 8,067 | Direct | COM | $16.27 | $131,250.09 | 35,176 |
| 10/12/2022 | DDS | 1,646 | Direct | COM | $15.40 | $25,348.40 | 51,176 |
| 08/03/2022 | DDS | 6,968 | Direct | COM | $18.00 | $125,424.00 | 38,967 |
| 08/01/2022 | DDS | 6,968 | Direct | COM | $16.64 | $115,947.52 | 45,935 |
| 07/05/2022 | DDS | 1,363 | Direct | COM | $14.50 | $19,763.50 | 52,903 |
| 1 You are at page 1 of 1 pages |
|
Transaction Type Key First letter: A = Acquired, D = Disposed Second letter: A = Grant, award or other acquisition pursuant to Rule 16b-3(d) C = Conversion of derivative security | D = Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | E = Expiration of short derivative position | F = Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. | G = Gift | H = Expiration (or cancellation) of long derivative position with value received | I = Discretionary transaction in accordance with Rule 16b-3(f) | J = Other | L = Small acquisition under Rule 16a-6 | M = Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | O = Exercise of out-of-the-money derivative security | P = Open market or private purchase | S = Open market or private sale | U = Disposition pursuant to a tender of shares in a change of control transaction | W = Acquisition or disposition by will or the laws of descent and distribution | X = Exercise of in-the-money or at-the-money derivative security | Z = Deposit into or withdrawal from voting trust |
 |
Send to Excel |
© 2000 - 2025 Zacks Investment Research